Virios Therapeutics (NASDAQ:VIRI) just reported results for the first quarter of 2024.
- Virios Therapeutics reported earnings per share of -7 cents. This was below the analyst estimate for EPS of -5 cents.
- The company did not report any revenue for the quarter.